Research helps to identify immunosuppressed people least likely to have COVID-19 antibodies

DRAFT

FOR IMMEDIATE RELEASE

Research helps to identify immunosuppressed people least likely to have COVID-19 antibodies

• One in five people with solid organ transplant, rare autoimmune disease or blood cancer affecting lymphocytes had no COVID-19 antibodies after three or more vaccinations
• More vaccinations, being younger and having previously had COVID-19 associated with the presence of antibodies
• Home antibody tests for at-risk groups could be used to target booster jabs and other preventative treatments

New research has identified which people with compromised immune systems are less likely to have COVID-19 antibodies - making them more vulnerable to a severe infection.

Around one in five people with solid organ transplant, rare autoimmune disease or blood cancer affecting lymphocytes had no COVID-19 antibodies after three or more vaccinations.

The MELODY study was carried out by a team of doctors and researchers from several institutions including Imperial College London, The Universities of Southampton, Nottingham, and Cambridge, Nottingham University Hospitals NHS Trust, NHS Blood and Transplant, the National Disease Registration Service at NHS England, and IPSOS MORI.

People were more likely to have antibodies if they were younger, had more vaccine doses (e.g. five vs three) or had previously had COVID-19. Some medications that weaken the immune system reduced the likelihood of having antibodies.

The findings published in The Lancet Rheumatology will help to better plan care and treatment for people living with these conditions. People who are less likely to have COVID-19 antibodies could be offered antibody testing and targeted interventions, such as further vaccine doses or preventative medicine. The absence of antibodies could also influence which immunotherapy medications are given to those with different underlying conditions.

Dr Michelle Willicombe, from the Department of Immunology & Inflammation at Imperial College London, who led the research, said: “We know from previous research that people who have a weakened immune system were more likely to catch COVID-19. They were also more likely to need to go into hospital for treatment or die from COVID-19.

“Vaccines trigger the immune system to make antibodies. But if your immune system is weak, you may not produce enough antibodies needed to fight infection and prevent serious illness. Clinically vulnerable patients who are at increased risk are encouraged to attend if they are invited for a booster vaccine, in order to get the best protection against COVID-19.”

People with suppressed immune systems could choose to enrol in the study if they had received at least 3 COVID-19 vaccine doses. More than 23 thousand people took part by doing a home finger-prick antibody test and reporting the results using an online portal.

Participants also provided personal details (such as their age, gender and ethnicity), information about their condition, and their COVID-19 history, including number of vaccinations.

Antibodies were found in 77 per cent of people who had a solid organ transplant, 79 per cent of those with a blood cancer, and 86 per cent with rare autoimmune disease.

“We now know that the majority of immunosuppressed people produce antibodies after having a COVID-19 vaccine,” says co-author of the study Professor Sean Lim from the University of Southampton. “In the future, we could offer home antibody tests to those who we know are least likely to have antibodies and provide them to have quick access to preventative treatments if this is the case. The findings could also help to develop bespoke booster vaccination schedules for different groups.”

Dr Peter Lanyon, Consultant Rheumatologist, Nottingham University Hospitals NHS Trust and Rare Diseases Clinical Lead, National Disease Registration Service, NHS England said: “This study demonstrates the utility of national rare disease registration to identify and invite whole population-based cohorts of people to participate in research that answers important clinical questions and can inform clinical practice and health policy.”

Antibody prevalence after 3 or more COVID-19 vaccine doses in 23,000 immunosuppressed individuals: a cross-sectional study from MELODY is available online.

The research was funded by Funding for the Medical Research Council and health charities including Kidney Research UK, Vasculitis UK, Blood Cancer UK, and Cystic Fibrosis Trust.

Contact

Steve Williams, Media Relations, University of Southampton press@soton.ac.uk or 023 8059 3212.

Notes for editors

1. Antibody prevalence after 3 or more COVID-19 vaccine doses in 23,000 immunosuppressed individuals: a cross-sectional study from MELODY is published in The Lancet Rheumatology and is available at https://www.sciencedirect.com/science/article/pii/S2665991323001601
2. For Interviews with Professor Sean Lim please contact Steve Williams, Media Relations, University of Southampton press@soton.ac.uk or 023 8059 3212.

Additional information

The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world’s challenges. We are among the top 100 institutions globally (QS World University Rankings 2023). Our academics are leaders in their fields, forging links with high-profile international businesses and organisations, and inspiring a 22,000-strong community of exceptional students, from over 135 countries worldwide. Through our high-quality education, the University helps students on a journey of discovery to realise their potential and join our global network of over 200,000 alumni. www.southampton.ac.uk

www.southampton.ac.uk/news/contact-press-team.page

Follow us on twitter: https://twitter.com/UoSMedia

Imperial College London is a global top ten university with a world-class reputation. The College's 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. The Research Excellence Framework (REF) 2021 found that it has a greater proportion of world-leading research than any other UK university, it was named University of the Year 2022 according to The Times and Sunday Times Good University Guide, University of the Year for Student Experience 2022 by the Good University Guide, and awarded a Queen’s Anniversary Prize for its COVID-19 response. https://www.imperial.ac.uk/